Enliven Therapeutics, Inc. (ELVN) stock
Close on Nov 13, 2026Market cap $3.58BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $3.58B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.08
- Dividend yield
- –
- Free cash flow yield
- -1.86%
Fundamentals
- Net income
- -$113.48M
- EPS, diluted
- -$1.71
- Free cash flow
- -$66.41M
- Book value per share
- $11.25
- Diluted shares
- 78M
Trading
- Next earnings
- Mar 2, 2027 (estimated, after the close)
- Previous close
- $48.31
- Open
- $48.22
- Day's range
- $46.96 – $49.13
- Volume
- 972,566
- Average volume (20 days)
- 1,590,654
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 0.94
- 52-week range
- $14.79 – $62.32
- RSI (14 days)
- 57.3
- Volatility (1 year)
- 78.0%
- Relative volume
- 0.79×
- WACC
- 9.8%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ELVN | S&P 500 | Difference | ELVN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +23.6% | -3.0% | +26.6 pts | ||
| 3 months | -15.9% | -2.8% | −13.2 pts | ||
| Year to date | +216.9% | +11.5% | +205.4 pts | ||
| 1 year | +140.7% | +13.5% | +127.3 pts | ||
| 3 years | +347.7% | +77.7% | +270.0 pts | +64.8% | +21.1% |
| 5 years | +241.7% | +72.6% | +169.1 pts | +27.9% | +11.5% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Enliven Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Update
- Results
About Enliven Therapeutics
Pharmaceutical Preparations
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies. The company applies a precision medicine approach rooted in validated biological targets and differentiated chemistry to improve survival outcomes and quality of life for patients. Its primary clinical program centers on ELVN-001, a potent and selective ATP-competitive tyrosine kinase inhibitor targeting the BCR-ABL gene fusion for individuals with chronic myeloid leukemia. In addition to its core oncology program, Enliven engages in research-stage opportunities across other medical areas, including discovery efforts directed toward Graves' disease.
Company profile, executives and historyEnliven Therapeutics stock: common questions
What is Enliven Therapeutics's stock price?
ELVN closed at $48.80 on Nov 13, 2026, up 1.01% on the day. Over the past 52 weeks it traded between $14.79 and $62.32.
What is Enliven Therapeutics's market cap?
Enliven Therapeutics was worth $3.58B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ELVN's P/E ratio?
Enliven Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.71), so it has no meaningful P/E ratio.
Does Enliven Therapeutics pay a dividend?
No. Enliven Therapeutics has not paid a cash dividend over the last twelve months.
When does Enliven Therapeutics report earnings next?
Enliven Therapeutics is expected to report Q4 FY2026 results on Mar 2, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ELVN stock performed over the past year?
Including dividends, ELVN returned +140.7% over the past year, against +13.5% for the S&P 500.
How many ELVN shares are sold short?
10M shares were sold short at the latest FINRA report, 18.22% of the float, or 5.7 days of average trading volume.
Who are Enliven Therapeutics's competitors?
Companies most similar to Enliven Therapeutics by business, industry and size include PRLD, COGT, APRE, NRIX, AVBP.
See a number that looks wrong?